U.S. House backs extension of FDA programme that incentivises rare disease drugs
The U.S. House of Representatives has passed legislation to reauthorise a key Food and Drug Administration programme designed to encourage the development of medicines for rare diseases, reviving a scheme that had lapsed amid debate over its cost and impact. The bill, passed on Dec. 1, extends the FDA’s Priority Review Voucher (PRV) programme, which…